Pharmaceutical News and Articles

Exercise Helps Colon Cancer Survivors Live Longer

Frequent exercise can help colon cancer survivors live longer, perhaps even outlasting average folks, a new study suggests. Colon cancer patients who were very

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xanthomatosis

Fainting: Simple Tips to Stay Safe

Fainting can be scary, but it s often harmless. Known medically as syncope, fainting happens when there s not enough blood flow to the brain, causing a brief lo

Coffee Leads U.S. Caffeine Intake as Tea Declines

about two to three 12-ounce cups of coffee. With a constantly evolving market of caffeinated beverages and the potential impact it has on beverage consumption p

More Than Two-Thirds of U.S. Counties Do Not Have a Gastroenterologist

About 69 percent of U.S. counties do not have a gastroenterologist, according to a research letter published online Feb. 6 in Gastroenterology.Xiaohan Ying, M.D

Black Patients With Cancer Still Have Higher Mortality Rates Than Whites

Cancer mortality has decreased among Black Americans, but they still have elevated mortality rates compared with White Americans, according to a study published

Postpandemic Hospital Occupancy Up to 73.5 Percent, Sparking Concern

Postpandemic hospital occupancy is higher than prepandemic and is expected to continue increasing without changes in the hospitalization rate or staffed hospita

Certain Glucose-Lowering Meds Associated With Lower Risk for COPD Exacerbations

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-lik

Olpasiran Leads to Significant Reduction in Oxidized Phospholipids

Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp a ) production, leads to a significant and sustained reduction in oxidized phospholipids (Ox

Acalabrutinib-Venetoclax Prolongs Survival in Previously Untreated Leukemia

For patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration acalabrutinib-venetoclax with or without obinutuzumab significantly pr